ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01697761
Recruitment Status : Completed
First Posted : October 2, 2012
Last Update Posted : November 20, 2014
Sponsor:
Information provided by (Responsible Party):
Shanghai Institute of Acupuncture, Moxibustion and Meridian

Brief Summary:
The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of active Crohn's disease. meanwhile, we are aim to observe the content of Inflammatory factors and Neurotransmitter before and after acupuncture and moxibustion therapy.

Condition or disease Intervention/treatment Phase
Crohn's Disease CAM Other: Treatment Group Other: Control Group Not Applicable

Detailed Description:

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of active Crohn's disease. meanwhile, we are aim to observe the content of Inflammatory factors and Neurotransmitter before and after acupuncture and moxibustion therapy.

Through treating active Crohn's disease by acupuncture and moxibustion therapies for 12 weeks, we are aim to observe the efficiency and the probably change of Inflammatory factors and Neurotransmitter of colonic mucosa and we may elucidate the mechanism of the efficiency of acupuncture and moxibustion therapy.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease and Its Regulation Mechanism to the Immune Homeostasis Mediated by Th17/Treg Cells
Study Start Date : September 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Group
treat by moxibustion and acupuncture
Other: Treatment Group
patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes,3 times a week for 12 weeks
Other Names:
  • acupuncture and moxibustion group
  • acupuncture and Herbs-partitioned moxibustion group

Experimental: Control Group
treat by Sham acupuncture and moxibustion
Other: Control Group
patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
Other Name: Sham acupuncture and moxibustion group




Primary Outcome Measures :
  1. CDAI [ Time Frame: 2 years ]
    Crohn's Disease Activity Index


Secondary Outcome Measures :
  1. Inflammatory factors [ Time Frame: 2 years ]
    Intestinal mucosa of Th17/Treg,IL-6,IL-17,IL-23,etc

  2. Neurotransmitter [ Time Frame: 2 years ]
    Intestinal mucosa of 5-HT,DA,SP,VIP and their receptors etc

  3. IBDQ [ Time Frame: 2 years ]
    Inflammatory Bowel Disease Questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18-70 years;
  • Crohn's Disease Activity Index [CDAI]>150 and <450;
  • not taking any medication or taking salicylates, prednisone ( dose≤ 15mg and at least have taken a month ), after entering the study the dose remained constant;
  • Not taking immunosuppressive agents or use " with " biological preparations within 3 months prior to entering the study
  • signing a written informed consent form.

Exclusion Criteria:

  • Severe Crohn's disease patients or patients in remission ( CDAI > 450 or < 150 );
  • The pregnancy or lactation period patients ;
  • patients associated with heart, brain, liver, kidney and hematopoietic system disease;
  • The psychiatric patients;
  • Patients with other serious diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01697761


Locations
China, Shanghai
Shanghai Institute of Acupuncture-Moxibustion and Merdian
Shanghai, Shanghai, China, 200030
Sponsors and Collaborators
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Investigators
Study Chair: Wu Huangan, PhD Shanghai Institute of Acupuncture, Moxibustion and Meridian

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Shanghai Institute of Acupuncture, Moxibustion and Meridian
ClinicalTrials.gov Identifier: NCT01697761     History of Changes
Other Study ID Numbers: SHACU-201202
First Posted: October 2, 2012    Key Record Dates
Last Update Posted: November 20, 2014
Last Verified: September 2012

Keywords provided by Shanghai Institute of Acupuncture, Moxibustion and Meridian:
Crohn's disease,acupuncture,moxibustion,inflammation factors

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases